METHOD OF PERFUSION COMPUTED TOMOGRAPHY IN DIAGNOSING PROSTATE DISEASES Russian patent published in 2019 - IPC A61B6/03 A61K49/04 A61P43/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to radiation diagnostics, urology and oncology, can be used for diagnostics of prostate. Perfusion computer tomography of prostate is performed. First, performing scanning in native mode. Upper limit of scanning passes along the upper contour of wings of iliac bones, the lower border – along the lower outline of ischial tuberosity. Then, on the obtained native images, sections are marked for subsequent perfusion scanning of the prostate: the initial scanning edge corresponds to a prostate base-level cut with overlapping of seminal vesicles, end section – to level of an apex of a gland. Volume of the contrast agent is calculated on basis of 0.3 g of iodine per 1 kg of the patient's weight. To construct perfusion maps, starting points are chosen – ellipse ROI: first point – to large arterial vessel, second – to prostate tissue. After that, calculation is performed in automatic mode with subsequent construction of functional maps. Calcificate, metal fragments and gas are not included in the zone of interest. Applied ellipse should not extend beyond the contrasted lumen of a vessel or tissue of the gland. Thereafter, on the functional maps obtained in the central and peripheral zones, at the level of the apex, base and in middle 1/3 gland, the regional blood flow values are determined on both sides: the volume of the regional blood flow (Blood Volume – BV), mean time of passage of blood (Mean Transit Time (MTT), rate of regional blood flow (Blood Flow – BF). At BF 27.96±6.3 ml/100 g/min, BV 3.51±1.0 ml/100 g and MTT 1.4±0.6 s diagnose prostate adenoma. At BF 52.05±9.14 ml/100 g/min, BV 8.4±0.74 ml/100 g and MTT 14.0±0.5 s is diagnosed with prostate adenocarcinoma. Nonionic iodine-containing radiopaque agents with active substance concentration of 350 or 370 mg/ml can be used.

EFFECT: method provides higher accuracy of examination, possibility of its carrying out in the presence of contraindications to MRI by differentiation of new growths of prostate when calculating BV, MTT and BF values for adenoma and adenocarcinoma of prostate.

1 cl, 8 dwg, 2 ex